Pulsed electromagnetic fields dosing impacts postoperative pain in breast reduction patients

Area of Science:

• Biomedical Engineering
• Pain Management
• Electrophysiology

Background:

• Pulsed electromagnetic fields (PEMF) are known to alleviate postoperative pain and reduce narcotic needs in breast surgery patients.
• PEMF influences nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) pathways, involving both stimulation and phosphodiesterase-mediated inhibition.
• The precise impact of these competing biochemical responses on optimal PEMF dosing for clinical efficacy remains unclear.

Purpose of the Study:

• To investigate the effectiveness of different pulsed electromagnetic field (PEMF) dosing regimens on postoperative pain and narcotic consumption in breast reduction surgery.
• To compare the efficacy of two active PEMF dosing schedules (15 min per 2 h and 5 min per 20 min) against a previously established effective regimen (20 min per 4 h) and sham controls.

Main Methods:

• A prospective, nonrandomized study involving two active PEMF treatment cohorts (Q2 and 5/20) in breast reduction patients.
• Comparison of postoperative visual analog scale (VAS) pain scores and narcotic usage with historical data from a double-blind study using a Q4 active PEMF regimen and sham controls.
• Analysis focused on pain levels at 24 hours and total narcotic consumption.

Main Results:

• The Q4 (active) and Q2 (active) PEMF regimens significantly accelerated postoperative pain reduction compared to sham controls (P < 0.01).
• The 5/20 (active) PEMF regimen showed no significant difference in pain reduction compared to the Q4 (sham) control (P = 0.451).
• Narcotic usage was significantly lower (2-fold) in the effective Q4 (active) and Q2 (active) groups compared to the 5/20 (active) and Q4 (sham) groups (P < 0.02).

Conclusions:

• The study demonstrates that specific PEMF dosing regimens (Q4/Q2) are effective in accelerating postoperative pain reduction following breast reduction surgery.
• The 5/20 PEMF dosing regimen was found to be ineffective, potentially due to accelerated phosphodiesterase inhibition of cGMP.
• These findings help establish dosing parameters for clinically beneficial PEMF applications in pain management.